'novel nanoemulsion/ self nanoemulsifying drug delivery system for enhanced oral bioavailability of hydrophobic selective ß1-adrenoreceptor blocker'

摘要

The present invention relates to a pharmaceutical formulation of a hydrophobic therapeutic agent talinolol (P-glycoprotein substrate) as an oral nanoemulsifying drug delivery system. More particularly, this invention relates to an oil-in water nanoemulsion delivery system of talinolol with a mean particle diameter of 10 to 200 run that comprises at least an oil having a concentration of greater than or equal to 10% (w/w) of triacetin. The invention also relates to a pharmaceutical composition in the form of a self-nanoemulsifying drug delivery system (SEDDS) comprising a therapeutic agent, a co-surfactant, oil, and a further surfactant. The invention further relates to a method of increasing the bioavailability of poorly water soluble and P-glycoprotein substrates.